The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma

Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immune oncology today is the lack of a predictive factor to identify this patient group.